-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55

Benzinga·05/14/2026 14:08:49
Listen to the news
Citizens analyst Jason N. Butler maintains Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform and lowers the price target from $62 to $55.